Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Stefan Laufer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Rats

Disorders

Osteoarthritis

Occupations

Drug Design

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
15
Gleiter, Christoph
15
Kammerer, Bernd
13
Martel-Pelletier, Johanne
13
Pelletier, Jean-Pierre
13
Tries, Susanne
11
Dannhardt, Gerd
7
Peifer, Christian
6
Boileau, Christelle
5
Kahlich, Rainer
5
Reboul, Pascal
4
Liebich, Hartmut
4
Lajeunesse, Daniel
4
Lang, Florian
4
Frickenschmidt, Antje
4
Wagner, Gerd

Sign-in to see all Coauthors

Publications

TOP 3
Ziegler Katharina; Hauser Dominik R J; Unger Anke; Albrecht Wolfgang; Laufer Stefan A
2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Foller M; Mahmud H; Gu S; Wang K; Floride E; Kucherenko Y; Luik S; Laufer S; Lang F
Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death.
Liedtke Andy J; Keck Peter R W E F; Lehmann Frank; Koeberle Andreas; Werz Oliver; Laufer Stefan A
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Stefan Laufer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ziegler Katharina; Hauser Dominik R J; Unger Anke; Albrecht Wolfgang; Laufer Stefan A
2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
ChemMedChem 2009;4(11):1939-48.
2009: Foller M; Mahmud H; Gu S; Wang K; Floride E; Kucherenko Y; Luik S; Laufer S; Lang F
Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2009;60(3):135-43.
2009: Liedtke Andy J; Keck Peter R W E F; Lehmann Frank; Koeberle Andreas; Werz Oliver; Laufer Stefan A
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX).
Journal of medicinal chemistry 2009;52(15):4968-72.
2009: Raynauld J-P; Martel-Pelletier J; Bias P; Laufer S; Haraoui B; Choquette D; Beaulieu A D; Abram F; Dorais M; Vignon E; Pelletier J-P;
Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI.
Annals of the rheumatic diseases 2009;68(6):938-47.
2009: Peifer Christian; Bühler Stefanie; Hauser Dominik; Kinkel Katrin; Totzke Frank; Schächtele Christoph; Laufer Stefan
Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.
European journal of medicinal chemistry 2009;44(4):1788-93.
2009: Laufer Stefan; Lehmann Frank
Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.
Bioorganic & medicinal chemistry letters 2009;19(5):1461-4.
2009: Lang Philipp A; Kasinathan Ravi S; Brand Verena B; Duranton Christophe; Lang Camelia; Koka Saisudha; Shumilina Ekaterina; Kempe Daniela S; Tanneur Valerie; Akel Ahmad; Lang Karl S; Foller Michael; Kun Jurgen F J; Kremsner Peter G; Wesselborg Sebastian; Laufer Stefan; Clemen Christoph S; Herr Claudia; Noegel Angelika A; Wieder Thomas; Gulbins Erich; Lang Florian; Huber Stephan M
Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009;24(5-6):415-28.
2009: Karcher Solveigh C; Laufer Stefan A
Successful structure-based design of recent p38 MAP kinase inhibitors.
Current topics in medicinal chemistry 2009;9(7):655-76.
2009: Henneges Carsten; Bullinger Dino; Fux Richard; Friese Natascha; Seeger Harald; Neubauer Hans; Laufer Stefan; Gleiter Christoph H; Schwab Matthias; Zell Andreas; Kammerer Bernd
Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection.
BMC cancer 2009;9():104.
2008: Bullinger Dino; Fux Richard; Nicholson Graeme; Plontke Stefan; Belka Claus; Laufer Stefan; Gleiter Christoph H; Kammerer Bernd
Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis.
Journal of the American Society for Mass Spectrometry 2008;19(10):1500-13.
2008: Koeberle Andreas; Siemoneit Ulf; Bühring Ulrike; Northoff Hinnak; Laufer Stefan; Albrecht Wolfgang; Werz Oliver
Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.
The Journal of pharmacology and experimental therapeutics 2008;326(3):975-82.
2008: Laufer S; Greim C; Luik S; Ayoub S S; Dehner F
Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity.
Inflammopharmacology 2008;16(4):155-61.
2008: Laufer Stefan A; Hauser Dominik R J; Domeyer David M; Kinkel Katrin; Liedtke Andy J
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Journal of medicinal chemistry 2008;51(14):4122-49.
2008: Peifer Christian; Selig Roland; Kinkel Katrin; Ott Dimitri; Totzke Frank; Schächtele Christoph; Heidenreich Regina; Röcken Martin; Schollmeyer Dieter; Laufer Stefan
Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
Journal of medicinal chemistry 2008;51(13):3814-24.
2008: Bullinger Dino; Fröhlich Holger; Klaus Fabian; Neubauer Hans; Frickenschmidt Antje; Henneges Carsten; Zell Andreas; Laufer Stefan; Gleiter Christoph H; Liebich Hartmut; Kammerer Bernd
Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer.
Analytica chimica acta 2008;618(1):29-34.
2008: Frickenschmidt Antje; Frohlich Holger; Bullinger Dino; Zell Andreas; Laufer Stefan; Gleiter Christoph H; Liebich Hartmut; Kammerer Bernd
Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(4):435-49.
2008: Lehmann Frank; Holm Melanie; Laufer Stefan
Three-component combinatorial synthesis of novel dihydropyrano[2,3-c]pyrazoles.
Journal of combinatorial chemistry 2008;10(3):364-7.
2008: Laufer Stefan A; Margutti Simona
Isoxazolone based inhibitors of p38 MAP kinases.
Journal of medicinal chemistry 2008;51(8):2580-4.
2008: Ospelt C; Kurowska-Stolarska M; Neidhart M; Michel B A; Gay R E; Laufer S; Gay S
The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands.
Annals of the rheumatic diseases 2008;67(4):524-9.
2008: Laufer Stefan; Koch Pierre
Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity.
Organic & biomolecular chemistry 2008;6(3):437-9.
2008: Peifer Christian; Urich Robert; Schattel Verena; Abadleh Mohammed; Röttig Marc; Kohlbacher Oliver; Laufer Stefan
Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
Bioorganic & medicinal chemistry letters 2008;18(4):1431-5.
2008: Raynauld Jean-Pierre; Martel-Pelletier Johanne; Abram François; Dorais Marc; Haraoui Boulos; Choquette Denis; Bias Peter; Emmert Karl H; Laufer Stefan; Pelletier Jean-Pierre
Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis.
Arthritis research & therapy 2008;10(6):R129.
2008: Holm Melanie; Lehmann Frank; Laufer Stefan
[Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research]
Pharmazie in unserer Zeit 2008;37(5):382-92.
2007: Margutti Simona; Laufer Stefan A
Are MAP kinases drug targets? Yes, but difficult ones.
ChemMedChem 2007;2(8):1116-40.
2007: Kammerer Bernd; Scheible Holger; Albrecht Wolfgang; Gleiter Christoph H; Laufer Stefan
Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(6):875-83.
2007: Hauser Dominik R J; Scior Thomas; Domeyer David M; Kammerer Bernd; Laufer Stefan A
Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.
Journal of medicinal chemistry 2007;50(9):2060-6.
2007: Kammerer B; Scheible H; Zurek G; Godejohann M; Zeller K P; Gleiter C H; Albrecht W; Laufer S
In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(3):280-97.
2007: Peifer Christian; Kinkel Katrin; Abadleh Mohammed; Schollmeyer Dieter; Laufer Stefan
From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors.
Journal of medicinal chemistry 2007;50(6):1213-21.
2007: Bullinger Dino; Neubauer Hans; Fehm Tanja; Laufer Stefan; Gleiter Christoph H; Kammerer Bernd
Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling.
BMC biochemistry 2007;8():25.
2006: Laufer Stefan A; Ahrens Gabriele M; Karcher Solveigh C; Hering Jörg S; Niess Raimund
Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.
Journal of medicinal chemistry 2006;49(26):7912-5.
2006: Peifer Christian; Krasowski Agata; Hämmerle Nina; Kohlbacher Oliver; Dannhardt Gerd; Totzke Frank; Schächtele Christoph; Laufer Stefan
Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor.
Journal of medicinal chemistry 2006;49(25):7549-53.
2006: Peifer Christian; Luik Sabine; Thuma Sabine; Herweh Yvonne; Laufer Stefan
Development and optimization of a non-radioactive JNK3 assay.
Combinatorial chemistry & high throughput screening 2006;9(8):613-8.
2006: Laufer Stefan; Linsenmaier Sabine
Development of a microsphere-based p38alpha kinase no-wash assay.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2006;11(5):528-36.
2006: Moreau Maxim; Boileau Christelle; Martel-Pelletier Johanne; Brunet Julie; Laufer Stefan; Pelletier Jean-Pierre
Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.
The Journal of rheumatology 2006;33(6):1176-83.
2006: Laufer Stefan A; Margutti Simona; Fritz Martina D
Substituted isoxazoles as potent inhibitors of p38 MAP kinase.
ChemMedChem 2006;1(2):197-207.
2006: Shumilina Ekaterina; Kiedaisch Valentin; Akkel Ahmad; Lang Philipp; Hermle Tobias; Kempe Daniela S; Huber Stephan M; Wieder Thomas; Laufer Stefan; Lang Florian
Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2006;18(4-5):233-42.
2006: Peifer Christian; Wagner Gerd; Laufer Stefan
New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.
Current topics in medicinal chemistry 2006;6(2):113-49.
2006: Kahlich Rainer; Gleiter Christoph H; Laufer Stefan; Kammerer Bernd
Quantitative determination of piritramide in human plasma and urine by off- and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(2):275-83.
2005: Scior Thomas; Guevara-García Antonio; Bernard Philippe; Do Quoc-Tuan; Domeyer David; Laufer Stefan
Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review.
Mini reviews in medicinal chemistry 2005;5(11):995-1008.
2005: Kammerer Bernd; Kahlich Rainer; Ufer Mike; Schenkel Andreas; Laufer Stefan; Gleiter Christoph H
Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.
Analytical and bioanalytical chemistry 2005;383(6):909-17.
2005: Laufer Stefan; Thuma Sabine; Peifer Christian; Greim Cornelia; Herweh Yvonne; Albrecht Angela; Dehner Frank
An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays.
Analytical biochemistry 2005;344(1):135-7.
2005: Ulbrich H; Soehnlein O; Xie X; Eriksson E E; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Biochemical pharmacology 2005;70(1):30-6.
2005: Kammerer Bernd; Frickenschmidt Antje; Gleiter Christoph H; Laufer Stefan; Liebich Hartmut
MALDI-TOF MS analysis of urinary nucleosides.
Journal of the American Society for Mass Spectrometry 2005;16(6):940-7.
2005: Kammerer Bernd; Frickenschmidt Antje; Müller Christa E; Laufer Stefan; Gleiter Christoph H; Liebich Hartmut
Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling.
Analytical and bioanalytical chemistry 2005;382(4):1017-26.
2005: Boileau C; Pelletier J-P; Tardif G; Fahmi H; Laufer S; Lavigne M; Martel-Pelletier J
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway.
Annals of the rheumatic diseases 2005;64(6):891-8.
2005: Lang P A; Kempe D S; Myssina S; Tanneur V; Birka C; Laufer S; Lang F; Wieder T; Huber S M
PGE(2) in the regulation of programmed erythrocyte death.
Cell death and differentiation 2005;12(5):415-28.
2005: Marcouiller Patrick; Pelletier Jean-Pierre; Guévremont Mélanie; Martel-Pelletier Johanne; Ranger Pierre; Laufer Stefan; Reboul Pascal
Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis.
The Journal of rheumatology 2005;32(4):704-12.
2005: Kammerer Bernd; Kahlich Rainer; Ufer Mike; Laufer Stefan; Gleiter Christoph H
Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.
Analytical biochemistry 2005;339(2):297-309.
2005: Laufer Stefan A; Domeyer David M; Scior Thomas R F; Albrecht Wolfgang; Hauser Dominik R J
Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
Journal of medicinal chemistry 2005;48(3):710-22.
2005: Pelletier Jean-Pierre; Boileau Christelle; Boily Martin; Brunet Julie; Mineau François; Geng Changshen; Reboul Pascal; Laufer Stefan; Lajeunesse Daniel; Martel-Pelletier Johanne
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.
Arthritis research & therapy 2005;7(5):R1091-102.
2004: Martel-Pelletier Johanne; Mineau François; Fahmi Hassan; Laufer Stefan; Reboul Pascal; Boileau Christelle; Lavigne Martin; Pelletier Jean-Pierre
Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
Arthritis and rheumatism 2004;50(12):3925-33.
2004: Laufer Stefan A; Zimmermann Werner; Ruff Kathrin J
Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
Journal of medicinal chemistry 2004;47(25):6311-25.
2004: Kammerer Bernd; Kahlich Rainer; Laufer Stefan; Li Shu-Ming; Heide Lutz; Gleiter Christoph H
Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species.
Analytical biochemistry 2004;335(1):17-29.
2004: Pelletier Jean-Pierre; Boileau Christelle; Brunet Julie; Boily Martin; Lajeunesse Daniel; Reboul Pascal; Laufer Stefan; Martel-Pelletier Johanne
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.
Bone 2004;34(3):527-38.
2004: Lajeunesse D; Martel-Pelletier J; Fernandes J C; Laufer S; Pelletier J-P
Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis.
Annals of the rheumatic diseases 2004;63(1):78-83.
2004: Kammerer Bernd; Kahlich Rainer; Ufer Mike; Laufer Stefan; Gleiter Christoph H
Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(4):458-64.
2003: Schwab Jan M; Beiter Thomas; Linder Juergen U; Laufer Stefan; Schulz Joachim E; Meyermann Richard; Schluesener Hermann J
COX-3--a virtual pain target in humans?
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(15):2174-5.
2003: Laufer Stefan
Role of eicosanoids in structural degradation in osteoarthritis.
Current opinion in rheumatology 2003;15(5):623-7.
2003: Laufer Stefan A; Wagner Gerd K; Kotschenreuther Dunja A; Albrecht W
Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Journal of medicinal chemistry 2003;46(15):3230-44.
2003: Laufer Stefan
International Conference on Inflammopharmacology -- VIII Side-Effects of Anti-inflammatory Drugs Symposium.
Expert opinion on investigational drugs 2003;12(7):1239-41.
2003: Wagner Gerd K; Kotschenreuther Dunja; Zimmermann Werner; Laufer Stefan A
Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
The Journal of organic chemistry 2003;68(11):4527-30.
2003: Wagner Irmela; Greim Cornelia; Laufer Stefan; Heide Lutz; Gleiter Christoph H
Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo.
Clinical pharmacology and therapeutics 2003;73(3):272-4.
2002: Laufer S; Greim C; Bertsche T
An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2002;10(12):961-7.
2002: Laufer Stefan A; Striegel Hans-Günther; Wagner Gerd K
Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
Journal of medicinal chemistry 2002;45(21):4695-705.
2002: Laufer Stefan; Wagner Gerd; Kotschenreuther Dunja
Ones, thiones, and N-oxides: an exercise in imidazole chemistry.
Angewandte Chemie (International ed. in English) 2002;41(13):2290-3.
2002: Boileau Christelle; Martel-Pelletier Johanne; Jouzeau Jean-Yves; Netter Patrick; Moldovan Florina; Laufer Stefan; Tries Susanne; Pelletier Jean-Pierre
Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
The Journal of rheumatology 2002;29(7):1446-53.
2002: Paredes Yosabeth; Massicotte Frédéric; Pelletier Jean-Pierre; Martel-Pelletier Johanne; Laufer Stefan; Lajeunesse Daniel
Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Arthritis and rheumatism 2002;46(7):1804-12.
2002: Laufer Stefan A; Wagner Gerd K
From imidazoles to pyrimidines: new inhibitors of cytokine release.
Journal of medicinal chemistry 2002;45(13):2733-40.
2002: Tries S; Neupert W; Laufer S
The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2002;51(3):135-43.
2002: Tries S; Laufer S; Radziwon P; Breddin H K
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2002;51(3):129-34.
2002: He Wendy; Pelletier Jean-Pierre; Martel-Pelletier Johanne; Laufer Stefan; Di Battista John A
Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.
The Journal of rheumatology 2002;29(3):546-53.
2002: Scior Thomas; Meneses Morales Iván; Garcés Eisele Solón Javier; Domeyer David; Laufer Stefan
Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review.
Archiv der Pharmazie 2002;335(11-12):511-25.
2002: Laufer Stefan
[What's in the future? New NSAIDs]
Pharmazie in unserer Zeit 2002;31(2):164-9.
2001: Jovanovic D V; Fernandes J C; Martel-Pelletier J; Jolicoeur F C; Reboul P; Laufer S; Tries S; Pelletier J P
In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.
Arthritis and rheumatism 2001;44(10):2320-30.
2001: Gay R E; Neidhart M; Pataky F; Tries S; Laufer S; Gay S
Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
The Journal of rheumatology 2001;28(9):2060-5.
1999: Laufer S; Zechmeister P; Klein T
Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1999;48(3):133-8.
1997: Laufer S; Striegel H G; Neher K; Zechmeister P; Donat C; Stolingwa K; Baur S; Tries S; Kammermeier T; Dannhardt G; Kiefer W
Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors.
Archiv der Pharmazie 1997;330(9-10):307-12.
1997: Abraham W M; Laufer S; Tries S
The effects of ML 3000 on antigen-induced responses in sheep.
Pulmonary pharmacology & therapeutics 1997;10(3):167-73.
1995: Dannhardt G; Lambrecht G; Laufer S; Mutschler E; Schweiger J
Regioisomeric 5(3)-aminomethyl-3(5)-phenylisoxazoles: synthesis, spectroscopic discrimination, and muscarinic activity.
Archiv der Pharmazie 1995;328(5):437-43.
1995: Heidemann A; Tries S; Laufer S; Augustin J
Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6- (4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.
Arzneimittel-Forschung 1995;45(4):486-90.
1995: Algate D R; Augustin J; Atterson P R; Beard D J; Jobling C M; Laufer S; Munt P L; Tries S
General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.
Arzneimittel-Forschung 1995;45(2):159-65.
1995: Laufer S; Tries S; Augustin J; Elsässer R; Albrecht W; Guserle R; Algate D R; Atterson P R; Munt P L
Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.
Arzneimittel-Forschung 1995;45(1):27-32.
1994: Laufer S; Tries S; Augustin J; Elsässer R; Algate D R; Atterson P R; Munt P L
Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat.
Arzneimittel-Forschung 1994;44(12):1329-33.
1994: Wallace J L; Carter L; McKnight W; Tries S; Laufer S
ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury.
European journal of pharmacology 1994;271(2-3):525-31.
1994: Laufer S A; Augustin J; Dannhardt G; Kiefer W
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
Journal of medicinal chemistry 1994;37(12):1894-7.
1994: Laufer S; Tries S; Augustin J; Dannhardt G
Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase.
Arzneimittel-Forschung 1994;44(5):629-36.
1993: Dannhardt G; Dominiak P; Laufer S
Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles.
Arzneimittel-Forschung 1993;43(4):441-4.
1991: Dannhardt G; Dominiak P; Laufer S
[Hypertensive action of 5-(beta-aminoethyl)aminoisoxazoles: synthesis and screening of isoxazolopyrazines and isoxazolodiazepines]
Archiv der Pharmazie 1991;324(3):141-8.
1990: Dannhardt G; Dominiak P; Laufer S
[Hypertensive acting 5-(beta-aminoethyl)aminoisoxazoles: synthesis and screening of derivatives with with partially rigid C-5 side chains and omega-position heterocyclics]
Archiv der Pharmazie 1990;323(9):571-8.
1990: Dannhardt G; Dominiak P; Laufer S
[Hypertensive action of 5-(omega-aminoalkyl)aminoisoxazole: synthesis and testing of compounds with a sulfamide or carboxyl group on the end of side chain]
Archiv der Pharmazie 1990;323(8):517-9.
1988: Dannhardt G; Laufer S; Lehr M
HPLC determination of etofenamate and flufenamic acid in biological material.
Clinical chemistry 1988;34(12):2580-1.

Sign-in to see more